β-blocker continuation after noncardiac surgery: A report from the Surgical Care and Outcomes Assessment Program

Steve Kwon, Rachel Thompson, Michael Florence, Ronald Maier, Lisa McIntyre, Terry Rogers, Ellen Farrohki, Mark Whiteford, David R. Flum

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: Despite limited evidence of effect, β-blocker continuation has become a national quality improvement metric. Objective: To determine the effect of β-blocker continuation on outcomes in patients undergoing elective noncardiac surgery. Design, Setting, and Patients: The Surgical Care and Outcomes Assessment Program is aWashington quality improvement benchmarking initiative based on clinical data from more than 55 hospitals. Linking Surgical Care and Outcomes Assessment Program data to Washington's hospital admission and vital status registries, we studied patients undergoing elective colorectal and bariatric surgical procedures at 38 hospitals between January 1, 2008, and December 31, 2009. Main Outcome Measures: Mortality, cardiac events, and the combined adverse event of cardiac events and/or mortality. Results: Of 8431 patients, 23.5% were taking β-blockers prior to surgery (mean [SD] age, 61.9 [13.7] years; 63.0% were women). Treatment with β-blockers was continued on the day of surgery and during the postoperative period in 66.0% of patients. Continuation of β-blockers both on the day of surgery and postoperatively improved from 57.2% in the first quarter of 2008 to 71.3% in the fourth quarter of 2009 (P value <.001). After adjusting for risk characteristics, failure to continue β-blocker treatment was associated with a nearly 2-fold risk of 90-day combined adverse event (odds ratio, 1.97; 95% CI, 1.19-3.26). The odds were even greater among patients with higher cardiac risk (odds ratio, 5.91; 95% CI, 1.40-25.00). The odds of combined adverse events continued to be elevated 1 year postoperatively (odds ratio, 1.66; 95% CI, 1.08-2.55). Conclusions: β-Blocker continuation on the day of and after surgery was associated with fewer cardiac events and lower 90-day mortality. A focus on β-blocker continuation is a worthwhile quality improvement target and should improve patient outcomes.

Original languageEnglish (US)
Pages (from-to)467-473
Number of pages7
JournalArchives of Surgery
Volume147
Issue number5
DOIs
StatePublished - May 1 2012

Fingerprint

Outcome Assessment (Health Care)
Quality Improvement
Ambulatory Surgical Procedures
Odds Ratio
Mortality
Elective Surgical Procedures
Benchmarking
Bariatric Surgery
Postoperative Period
Registries
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Kwon, S., Thompson, R., Florence, M., Maier, R., McIntyre, L., Rogers, T., ... Flum, D. R. (2012). β-blocker continuation after noncardiac surgery: A report from the Surgical Care and Outcomes Assessment Program. Archives of Surgery, 147(5), 467-473. https://doi.org/10.1001/archsurg.2011.1698

β-blocker continuation after noncardiac surgery : A report from the Surgical Care and Outcomes Assessment Program. / Kwon, Steve; Thompson, Rachel; Florence, Michael; Maier, Ronald; McIntyre, Lisa; Rogers, Terry; Farrohki, Ellen; Whiteford, Mark; Flum, David R.

In: Archives of Surgery, Vol. 147, No. 5, 01.05.2012, p. 467-473.

Research output: Contribution to journalArticle

Kwon, S, Thompson, R, Florence, M, Maier, R, McIntyre, L, Rogers, T, Farrohki, E, Whiteford, M & Flum, DR 2012, 'β-blocker continuation after noncardiac surgery: A report from the Surgical Care and Outcomes Assessment Program', Archives of Surgery, vol. 147, no. 5, pp. 467-473. https://doi.org/10.1001/archsurg.2011.1698
Kwon, Steve ; Thompson, Rachel ; Florence, Michael ; Maier, Ronald ; McIntyre, Lisa ; Rogers, Terry ; Farrohki, Ellen ; Whiteford, Mark ; Flum, David R. / β-blocker continuation after noncardiac surgery : A report from the Surgical Care and Outcomes Assessment Program. In: Archives of Surgery. 2012 ; Vol. 147, No. 5. pp. 467-473.
@article{02dea800a5a4458ab42b0ba72c130179,
title = "β-blocker continuation after noncardiac surgery: A report from the Surgical Care and Outcomes Assessment Program",
abstract = "Background: Despite limited evidence of effect, β-blocker continuation has become a national quality improvement metric. Objective: To determine the effect of β-blocker continuation on outcomes in patients undergoing elective noncardiac surgery. Design, Setting, and Patients: The Surgical Care and Outcomes Assessment Program is aWashington quality improvement benchmarking initiative based on clinical data from more than 55 hospitals. Linking Surgical Care and Outcomes Assessment Program data to Washington's hospital admission and vital status registries, we studied patients undergoing elective colorectal and bariatric surgical procedures at 38 hospitals between January 1, 2008, and December 31, 2009. Main Outcome Measures: Mortality, cardiac events, and the combined adverse event of cardiac events and/or mortality. Results: Of 8431 patients, 23.5{\%} were taking β-blockers prior to surgery (mean [SD] age, 61.9 [13.7] years; 63.0{\%} were women). Treatment with β-blockers was continued on the day of surgery and during the postoperative period in 66.0{\%} of patients. Continuation of β-blockers both on the day of surgery and postoperatively improved from 57.2{\%} in the first quarter of 2008 to 71.3{\%} in the fourth quarter of 2009 (P value <.001). After adjusting for risk characteristics, failure to continue β-blocker treatment was associated with a nearly 2-fold risk of 90-day combined adverse event (odds ratio, 1.97; 95{\%} CI, 1.19-3.26). The odds were even greater among patients with higher cardiac risk (odds ratio, 5.91; 95{\%} CI, 1.40-25.00). The odds of combined adverse events continued to be elevated 1 year postoperatively (odds ratio, 1.66; 95{\%} CI, 1.08-2.55). Conclusions: β-Blocker continuation on the day of and after surgery was associated with fewer cardiac events and lower 90-day mortality. A focus on β-blocker continuation is a worthwhile quality improvement target and should improve patient outcomes.",
author = "Steve Kwon and Rachel Thompson and Michael Florence and Ronald Maier and Lisa McIntyre and Terry Rogers and Ellen Farrohki and Mark Whiteford and Flum, {David R.}",
year = "2012",
month = "5",
day = "1",
doi = "10.1001/archsurg.2011.1698",
language = "English (US)",
volume = "147",
pages = "467--473",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - β-blocker continuation after noncardiac surgery

T2 - A report from the Surgical Care and Outcomes Assessment Program

AU - Kwon, Steve

AU - Thompson, Rachel

AU - Florence, Michael

AU - Maier, Ronald

AU - McIntyre, Lisa

AU - Rogers, Terry

AU - Farrohki, Ellen

AU - Whiteford, Mark

AU - Flum, David R.

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Background: Despite limited evidence of effect, β-blocker continuation has become a national quality improvement metric. Objective: To determine the effect of β-blocker continuation on outcomes in patients undergoing elective noncardiac surgery. Design, Setting, and Patients: The Surgical Care and Outcomes Assessment Program is aWashington quality improvement benchmarking initiative based on clinical data from more than 55 hospitals. Linking Surgical Care and Outcomes Assessment Program data to Washington's hospital admission and vital status registries, we studied patients undergoing elective colorectal and bariatric surgical procedures at 38 hospitals between January 1, 2008, and December 31, 2009. Main Outcome Measures: Mortality, cardiac events, and the combined adverse event of cardiac events and/or mortality. Results: Of 8431 patients, 23.5% were taking β-blockers prior to surgery (mean [SD] age, 61.9 [13.7] years; 63.0% were women). Treatment with β-blockers was continued on the day of surgery and during the postoperative period in 66.0% of patients. Continuation of β-blockers both on the day of surgery and postoperatively improved from 57.2% in the first quarter of 2008 to 71.3% in the fourth quarter of 2009 (P value <.001). After adjusting for risk characteristics, failure to continue β-blocker treatment was associated with a nearly 2-fold risk of 90-day combined adverse event (odds ratio, 1.97; 95% CI, 1.19-3.26). The odds were even greater among patients with higher cardiac risk (odds ratio, 5.91; 95% CI, 1.40-25.00). The odds of combined adverse events continued to be elevated 1 year postoperatively (odds ratio, 1.66; 95% CI, 1.08-2.55). Conclusions: β-Blocker continuation on the day of and after surgery was associated with fewer cardiac events and lower 90-day mortality. A focus on β-blocker continuation is a worthwhile quality improvement target and should improve patient outcomes.

AB - Background: Despite limited evidence of effect, β-blocker continuation has become a national quality improvement metric. Objective: To determine the effect of β-blocker continuation on outcomes in patients undergoing elective noncardiac surgery. Design, Setting, and Patients: The Surgical Care and Outcomes Assessment Program is aWashington quality improvement benchmarking initiative based on clinical data from more than 55 hospitals. Linking Surgical Care and Outcomes Assessment Program data to Washington's hospital admission and vital status registries, we studied patients undergoing elective colorectal and bariatric surgical procedures at 38 hospitals between January 1, 2008, and December 31, 2009. Main Outcome Measures: Mortality, cardiac events, and the combined adverse event of cardiac events and/or mortality. Results: Of 8431 patients, 23.5% were taking β-blockers prior to surgery (mean [SD] age, 61.9 [13.7] years; 63.0% were women). Treatment with β-blockers was continued on the day of surgery and during the postoperative period in 66.0% of patients. Continuation of β-blockers both on the day of surgery and postoperatively improved from 57.2% in the first quarter of 2008 to 71.3% in the fourth quarter of 2009 (P value <.001). After adjusting for risk characteristics, failure to continue β-blocker treatment was associated with a nearly 2-fold risk of 90-day combined adverse event (odds ratio, 1.97; 95% CI, 1.19-3.26). The odds were even greater among patients with higher cardiac risk (odds ratio, 5.91; 95% CI, 1.40-25.00). The odds of combined adverse events continued to be elevated 1 year postoperatively (odds ratio, 1.66; 95% CI, 1.08-2.55). Conclusions: β-Blocker continuation on the day of and after surgery was associated with fewer cardiac events and lower 90-day mortality. A focus on β-blocker continuation is a worthwhile quality improvement target and should improve patient outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84861406263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861406263&partnerID=8YFLogxK

U2 - 10.1001/archsurg.2011.1698

DO - 10.1001/archsurg.2011.1698

M3 - Article

C2 - 22249847

AN - SCOPUS:84861406263

VL - 147

SP - 467

EP - 473

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 5

ER -